Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04430465
Other study ID # D225
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 3, 2020
Est. completion date May 4, 2021

Study information

Verified date January 2021
Source University of Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

KORN investigates the effects of wholegrain oat and rye intake on health and cognitive wellbeing in children with overweight.


Description:

The purpose of KORN is to investigate the effects of wholegrain oat and rye intake on cardiometabolic health in slightly overweight 8-13-year-old children. Moreover, KORN aims to investigate effects on body weight and body composition, inflammatory markers, gastrointestinal wellbeing and cognitive function and explore the potential underlying mechanisms through assessment of changes in the children's gut microbiota as well as potential genotype-dependent and sex-specific effects. The study has a randomized controlled cross-over design. In two 8-week dietary periods the children will receive grain products (cereals, breads, pasta etc) with either high or low content of wholegrain from oat and rye in random order. Measurements and biological sampling will be performed at 0, 8 and 16 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date May 4, 2021
Est. primary completion date May 4, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 13 Years
Eligibility Inclusion Criteria: - Boys and girls 8-13 years of age - Be overweight i.e. have a parent-reported BMI of at least +1 standard deviation above the median according to the age and sex-standardized Danish growth curves - Be healthy - Like grain products and eat them daily - Speak Danish in order to understand the study procedures - At least one parent must read and speak Danish, in order to be properly informed about the study procedures - Parents must have freezer capacity for 2 weeks bread provision Exclusion Criteria: - Allergy or intolerance to the study foods, including gluten - Use of dietary fiber supplements (e.g. HUSK) or probiotic supplements - Dieting or on a special diet - Serious chronic illnesses and diseases that may interfere with study outcomes - Use of medication that may affect study outcomes, including use of antibiotics the last month - Concomitant participation in other studies involving dietary supplements, drugs or blood sampling - Living in a household with another participating child

Study Design


Intervention

Dietary Supplement:
Grain products high in wholegrains from oat and rye
A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
Grain products low in wholegrains
A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products

Locations

Country Name City State
Denmark Department of Nutrition, Exercise and Sports, University of Copenhagen Frederiksberg

Sponsors (2)

Lead Sponsor Collaborator
University of Copenhagen Chalmers University of Technology

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Dietary intake assessed by 4-day dietary record 16 weeks
Other Physical activity assessed by questionnaire 16 weeks
Other Sociodemographic characteristics assessed by questionnaire at baseline
Other Pubertal development stage assessed by the Tanner scales at baseline
Other General satisfaction assessed by questionnaire 16 weeks
Other Liking of study products assessed by questionnaire 16 weeks
Other Alkylresorcinols (compliance) by fasting blood sample 16 weeks
Other Android fat mass index by Dual-energy X-ray Absorptiometry 16 weeks
Other Gynoid fat mass index by Dual-energy X-ray Absorptiometry 16 weeks
Other Android:gynoid fat mass ratio by Dual-energy X-ray Absorptiometry 16 weeks
Other Immune cell count by fasting blood sample 16 weeks
Other Interleukin 6 (IL-6) by fasting blood sample 16 weeks
Other Interleukin 1ß (IL-1ß) by fasting blood sample 16 weeks
Other Tumor necrosis factor alpha (TNFa) by fasting blood sample 16 weeks
Other Bone Mineral Density by Dual-energy X-ray Absorptiometry 16 weeks
Other Bone Mineral Content by Dual-energy X-ray Absorptiometry 16 weeks
Other Bone area by Dual-energy X-ray Absorptiometry 16 weeks
Other Gut microbiome composition determined by high throughput sequencing and qPCR by fecal sample 16 weeks
Other Short chain fatty acids by fasting blood sample 16 weeks
Other Short chain fatty acids by fecal sample 16 weeks
Other Bile acids by fasting blood sample 16 weeks
Other Bile acids by fecal sample 16 weeks
Other Fatty acid composition by fasting blood sample 16 weeks
Other C-peptide by fasting blood sample 16 weeks
Other Epigenetics by fasting blood sample 16 weeks
Other Metabolomics by fasting blood sample 16 weeks
Other Metabolomics by fecal sample 16 weeks
Other Proteomics by fasting blood sample 16 weeks
Other Proteomics by fecal sample 16 weeks
Other Genotypes by fasting blood sample 16 weeks
Other Adiponectin by fasting blood sample 16 weeks
Other Leptin by fasting blood sample 16 weeks
Other Appetite hormones by fasting blood sample 16 weeks
Other Testosterone by fasting blood sample 16 weeks
Other Estrogen by fasting blood sample 16 weeks
Other Gonadotropins by fasting blood sample 16 weeks
Primary Low density lipoprotein cholesterol by fasting blood sample 16 weeks
Primary Insulin by fasting blood sample 16 weeks
Secondary Height by stadiometer 16 weeks
Secondary Weight by digital scale 16 weeks
Secondary Body Mass Index z-score by height and weight measurements 16 weeks
Secondary Waist circumference by measuring tape 16 weeks
Secondary Fat mass index by Dual-energy X-ray Absorptiometry 16 weeks
Secondary Fat free mass index by Dual-energy X-ray Absorptiometry 16 weeks
Secondary Systolic blood pressure by digital device 16 weeks
Secondary Diastolic blood pressure by digital device 16 weeks
Secondary Heart rate by digital device 16 weeks
Secondary Glucose by fasting blood sample 16 weeks
Secondary Glycosylated hemoglobin (HbA1c) by fasting blood sample 16 weeks
Secondary Triacylglycerol by fasting blood sample 16 weeks
Secondary High density lipoprotein cholesterol by fasting blood sample 16 weeks
Secondary Total cholesterol by fasting blood sample 16 weeks
Secondary High sensitivity C-reactive protein by fasting blood sample 16 weeks
Secondary Attention assessed by d2 test of attention 16 weeks
Secondary Inhibition assessed by Stroop color and word test 16 weeks
Secondary Processing speed assessed by d2 test of attention and Stroop color and word test 16 weeks
Secondary Working memory assessed by Kim's game 16 weeks
Secondary Socio-emotional skills assessed by parent reported Strengths and Difficulties Questionnaire 16 weeks
Secondary Stool consistency assessed by the Bristol stool scale 16 weeks
Secondary Gastrointestinal wellbeing assessed by questionnaire 16 weeks
Secondary Prevalence of overweight By the International Obesity Task Force criteria 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02829229 - Community-based Obesity Treatment in African American Women After Childbirth N/A
Terminated NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4